Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease

被引:15
|
作者
Saboo, Ujwala S. [1 ]
Amparo, Francisco [1 ]
Shikari, Hasanain [1 ]
Jurkunas, Ula V. [1 ]
Dana, Reza [1 ]
机构
[1] Harvard Univ, Massachusetts Eye & Ear Infirm, Cornea Serv, Dept Ophthalmol,Med Sch, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
Graft-versus-host disease; Cataract; Phacoemulsification; Ocular surface disease; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; POSTERIOR CAPSULE OPACIFICATION; STEM-CELL TRANSPLANTATION; QUALITY-OF-LIFE; CATARACT-SURGERY; CONTAMINATION RISK; PROBABILITY; PREVALENCE; MANAGEMENT;
D O I
10.1007/s00417-015-2940-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The purpose of this study was to evaluate the outcomes of phacoemulsification in patients with ocular graft-versus-host disease (GVHD). The occurrence of cataracts, cataract surgery, and its outcomes were analyzed in the medical records of 229 patients (458 eyes) with ocular GVHD. Outcome measures included pre- and postoperative corrected distance visual acuity (CDVA) and the rate of postoperative complications. Of the 458 eyes evaluated, 58 were pseudophakic; from the 400 phakic eyes, 238 (59 %) presented with cataracts and 62 (26 %) underwent cataract surgery. Analysis of postoperative complications and visual outcomes at 1 month was performed in 51 eyes in which detailed surgical and immediate postoperative records were available. Preoperatively, the mean CDVA was 0.67 +/- 0.57 LogMAR (Snellen 20/93), improving postoperatively to 0.17 +/- 0.18 (Snellen 20/29) at 1 month (P < 0.0001), and to 0.13 +/- 0.14 (Snellen 20/26) by the final follow-up visit (P < 0.0001). Postoperative complications included corneal epithelial defects (8 %), filamentary keratitis (6 %), worsening of corneal epitheliopathy (16 %), posterior capsular opacification (18 %), and cystoid macular edema (4 %). A corrected distance visual acuity of 20/30 or better was achieved in 87 % of the eyes; suboptimal CDVA improvement was attributable to severe ocular surface disease, pre-existing advanced glaucoma, and prior macular surgery. Phacoemulsification in patients with chronic ocular GVHD is a safe and efficacious procedure resulting in significant visual improvement. Overall, postoperative adverse events responded well to timely management.
引用
收藏
页码:901 / 907
页数:7
相关论文
共 50 条
  • [31] Ocular pain in ocular graft-versus-host disease patients with neurotrophic keratopathy
    Wang, Shudan
    Singh, Rohan Bir
    Yuksel, Erdem
    Musayeva, Aytan
    Sinha, Shruti
    Taketani, Yukako
    Dohlman, Thomas H.
    Dana, Reza
    OCULAR SURFACE, 2022, 26 : 142 - 147
  • [32] Chronic graft-versus-host disease
    Rorvik, Synne Dragesund
    Abrahamsen, Ingerid Weum
    Myhre, Anders Eivind
    Vo, Camilla Dao
    Odegaard, Eva Meling
    Bruserud, Oystein
    Gedde-Dahl, Tobias
    Tvedt, Tor Henrik Anderson
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2023, 143 (04) : 337 - 341
  • [33] Chronic graft-versus-host disease
    Bolanos-Meade, Javier
    Vogelsang, Georgia B.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (20) : 1974 - 1986
  • [34] Chronic graft-versus-host disease
    Galbizo, Ellaine
    Williams, Lori A.
    ONCOLOGY NURSING FORUM, 2006, 33 (05) : 881 - 883
  • [35] Chronic graft-versus-host disease
    Cutler, C
    Antin, JH
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (02) : 126 - 131
  • [36] Chronic graft-versus-host disease
    Margolis, J
    Vogelsang, G
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (03): : 339 - 346
  • [37] CHRONIC GRAFT-VERSUS-HOST DISEASE
    ATKINSON, K
    BONE MARROW TRANSPLANTATION, 1990, 5 (02) : 69 - 82
  • [38] Chronic graft-versus-host disease
    Horwitz, ME
    Sullivan, KM
    BLOOD REVIEWS, 2006, 20 (01) : 15 - 27
  • [39] Chronic graft-versus-host disease
    Lee, SJ
    Vogelsang, G
    Flowers, MED
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (04) : 215 - 233
  • [40] Ocular graft-versus-host disease [Okuläre Graft-versus-Host-Disease]
    Dietrich-Ntoukas T.
    Steven P.
    Der Ophthalmologe, 2015, 112 (12): : 1027 - 1040